Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 220,000 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 220,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $4.20, for a total value of $924,000.00. Following the completion of the sale, the director owned 6,429,863 shares of the company’s stock, valued at $27,005,424.60. This trade represents a 3.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, January 6th, Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $4.36, for a total transaction of $959,200.00.
• On Tuesday, December 2nd, Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $4.37, for a total transaction of $961,400.00.

Recursion Pharmaceuticals Stock Performance

RXRX opened at $3.98 on Friday. The firm’s fifty day simple moving average is $4.45 and its two-hundred day simple moving average is $4.94. Recursion Pharmaceuticals, Inc. has a 52-week low of $3.54 and a 52-week high of $12.36. The company has a market cap of $2.07 billion, a price-to-earnings ratio of -2.21 and a beta of 0.95. The company has a quick ratio of 4.60, a current ratio of 4.60 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Wednesday, November 5th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.02. The business had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $19.36 million. Recursion Pharmaceuticals had a negative net margin of 1,637.81% and a negative return on equity of 72.74%. The company’s quarterly revenue was down 80.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.34) earnings per share. Equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on RXRX. JPMorgan Chase & Co. raised Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $10.00 to $11.00 in a research note on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, January 22nd. Morgan Stanley set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Finally, UBS Group set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $9.40.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of hedge funds have recently modified their holdings of RXRX. TD Waterhouse Canada Inc. raised its stake in Recursion Pharmaceuticals by 64.1% during the second quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock worth $29,000 after purchasing an additional 2,200 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth approximately $31,000. Sequoia Financial Advisors LLC purchased a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at approximately $41,000. Caitong International Asset Management Co. Ltd lifted its holdings in Recursion Pharmaceuticals by 97.2% in the second quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company’s stock valued at $46,000 after acquiring an additional 4,446 shares during the last quarter. Finally, Allworth Financial LP grew its position in Recursion Pharmaceuticals by 85.6% in the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock worth $47,000 after acquiring an additional 4,403 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.